Sen. Cassidy: Higher Biologics Prices Would Increase Biosimilar Uptake

December 8, 2016 at 8:08 PM
Sen. Bill Cassidy (R-LA) argued Wednesday (Dec. 7) that making patients pay more for innovator biologics would increase uptake in biosimilars, while also maintaining that his office is exploring ways to address drug pricing in the upcoming user fee authorizations. Uptake and availability of biosimilars, which many have seen as a way to address the high cost of biologic medicines, was a focus of key lawmakers during a Wednesday policy briefing on biosimilars hosted by The Atlantic . Cassidy cited...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.